About vaccines

Researchers examined neutralizing antibody levels in 48 vaccinated health care workers against the major SARS-CoV-2 variants. //10.12.2021

New study reveals that people with HIV are at a high risk of breakthrough COVID-19 infection in comparison to people without HIV, and that booster vaccinations can be protective for those living with HIV. // 9.12.2021

Most young people under the age of 21 who developed suspected COVID-19 vaccine-related heart muscle inflammation known as myocarditis had mild symptoms that improved quickly, according to new research published today in the American Heart Association's flagship journal Circulation. // 6.12.2021

Researchers measured SARS-CoV-2–specific antibody, memory B cell, and memory T cell responses in a group of healthy subjects who generated primary immune responses to two doses of mRNA vaccine compared to a group of SARS-CoV-2–recovered vaccines. / 6.12.2021

A new study investigates uses seven different COVID-19 vaccines as the third dose to boost immunity in vulnerable patients. // 6.12.2021

In a recent study conducted at Yale University, USA, scientists have investigated the immunogenicity of mRNA-based coronavirus disease 2019 (COVID-19) vaccine candidates encoding the spike proteins of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The findings reveal that the vaccines induce robust immune responses against SARS-CoV-2 variants. // 6.12.2021

In a Japanese study, smoking, HNB tobacco products, and alcohol use have been shown to impair the immunological response to the COVID-19 vaccination. // 2.12.2021

When it comes to determining when vaccine boosters and pandemic policy interventions should occur, understanding the duration and effectiveness of severe acute respiratory syndrome coronavirus 2... // 2.12.2021

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force. // 1.12.2021

New study findings suggest that booster vaccination with an mRNA-based vaccine has the highest immunogenicity against the COVID-19 Delta variant. // 1.12.2021

Suomessa rokotukset estivät arvion mukaan 72 prosenttia yli 60-vuotiaiden koronakuolemista. // 1.12.2021

Scientists have recently compared the levels of antibody concentrations in unvaccinated, SARS-CoV-2 convalescent individuals and COVID-19 specific antibodies in vaccinated individuals. // 30.11.2021

A recent study, currently available on the medRxiv* preprint server, has shown how longer dosing intervals of vaccines against coronavirus disease (COVID-19) may be able to minimize mortality in low- and middle-income countries in the WHO European region – and significantly change our vaccination strategy. // 30.11.2021

Researchers compared the distribution of SARS-CoV-2 genotypes to the prevalence of SARS-CoV-2 variants. // 28.11.2021

A team of UK-based scientists has recently evaluated the effectiveness of coronavirus disease 2019 (COVID-19) vaccines in preventing household transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in England. // 28.11.2021

Researchers performed a time-series analysis to evaluate the effectiveness of COVID-19 vaccination in the U.S. CG against SARS-CoV-2 infection. // 28.11.2021

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant (B.1.621, B.1.621.1) has been tagged as a Variant Being Monitored (VBM), and as of August 30, 2021, it had been detected in 39 countries. // 28.11.2021

Researchers assess the neutralizing antibody titers in BNT162b2-vaccinated people against SARS-CoV-2 isolates from the Mu, Gamma, and B.1.111 lineages. // 28.11.2021

In this study, published on the medRxiv* preprint server, the humoral response to SARS-CoV-2 was assessed before and after three months of administration of the BNT162b2 mRNA COVID-19 vaccination (Pfizer-BioNTech). In addition, elders' humoral responses were compared to those of a younger group, and a functional neutralization experiment against the Wuhan-Hu-1 (WH1) virus and the Delta variant was carried out. // 23.11.2021

Indian researchers determine the magnitude, quality, and persistence of cellular and humoral memory responses after vaccination with BBV152/Covaxin. // 23.11.2021

Scientists have conducted a systematic review of published studies investigating the duration of efficacy of COVID-19 vaccines against SARS-CoV-2 infection and disease severity. // 23.11.2021

New research from the Centers for Disease Control & Prevention (CDC) suggest vaccines are highly protective against severe acute respiratory coronavirus 2 (SARS-CoV-2). Two doses of the Pfizer-BioNTech vaccine showed a 93% effectiveness against hospitalization. The findings add to a previous clinical trial that found vaccinated adolescents with 100% protection against SARS-CoV-2 infections. // 23.11.2021

Nature - Vaccines reduce the risk of developing COVID-19 — but studies disagree on their protective effect against long COVID. // 23.11.2021

Nature - Preprint data show that a three-dose combo of Soberana jabs has 92.4% efficacy in clinical trials. // 22.11.2021

New research from Japan found several risk factors associated with greater waning immunity after vaccination. Old age and smoking were amongst those with some of the lowest antibody titers. Women more than men were also more likely to experience a rapid decline in antibody levels 3 to 6 months after receiving their second Pfizer-BioNTech dose. // 21.11.2021

A study currently available on the medRxiv* preprint server has demonstrated that the incidence and mortality rates of coronavirus disease 2019 (COVID-19) in the US can be significantly reduced at the population level by increasing vaccinate rates from 40% to 80%. // 19.11.2021

In a new study, researchers from several British institutes estimated the effectiveness of booster vaccination against symptomatic COVID-19 in adults aged 50 years and older. // 18.11.2021

A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants. // 18.11.2021

In a recent study published in the Lancet Microbe journal, Australian researchers studied whether in-vitro neutralization titers could predict vaccine protection from SARS-CoV-2 variants. // 17.11.2021

Now, researchers from Public Health Services Israel have been investigating a new variant called Lambda to see if it qualifies as a variant of concern. Their research is published in the journal Eurosurveillance. // 16.11.2021